Phibro Animal Health Corp. (PAHC)

38.82 +0.84 (+2.21%) USD  |  NASDAQ  |  Oct 16, 16:00
38.83 +0.01 (+0.03%) After-Hours: 20:00
More

Phibro Animal Health Research and Development Expense (Annual) : 24.55M for June 30, 2026

Research and Development Expense (Annual) Chart

Historical Research and Development Expense (Annual) Data

View and export this data back to 2011. Start Trial.
Date Value
June 30, 2026 24.55M
June 30, 2025 23.73M
June 30, 2024 29.19M
June 30, 2023 24.40M
June 30, 2022 20.83M
June 30, 2021 17.76M
June 30, 2020 13.74M
June 30, 2019 12.08M
Date Value
June 30, 2018 9.998M
June 30, 2017 9.442M
June 30, 2016 11.03M
June 30, 2015 9.511M
June 30, 2014 8.212M
June 30, 2013 6.638M
June 30, 2012 7.189M
June 30, 2011 6.807M

R&D Expense Definition

R&D expense is a line item from many companies' income statements.

Read full definition.

Research and Development Expense (Annual) Range, Past 5 Years

View Research and Development Expense (Annual) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Research and Development Expense (Annual) Benchmarks

View Research and Development Expense (Annual) Benchmarks
Start Trial
Globus Medical, Inc. 146.94M
Corcept Therapeutics, Inc. 254.91M
Zoetis, Inc. 698.00M
Abbott Laboratories 2.889B
Prestige Consumer Healthcare, Inc. --